Teleflex Incorporated (TFX) has acquired Semprus BioSciences, a biomedical company and spin out from Massachusetts Institute of Technology or MIT. This purchase includes the core Semprus Sustain Technology. Teleflex said the transaction brings to it an innovative and patented platform technology that serves as the basis for next-generation medical devices. The technology is designed to provide the benefits of reducing complications such as thrombosis and microbial adhesion over long durations.
Sustain is a long-lasting, covalently bonded, non-leaching polymer that is designed to reduce the attachment of platelets and blood proteins at the device surface. The initial focus for the technology is its use in vascular device applications, and a Semprus Sustain coated Peripherally Inserted Central Catheter is currently pending 510(k) clearance from the Food and Drug Administration. Sustain is also pending CE Mark approval in Europe.
According to the deal, Teleflex has acquired Semprus BioSciences for an upfront payment of $30 million. Teleflex may be required to make certain additional payments based upon the achievement of certain regulatory and revenue milestones over the next several years.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.